Tuesday, 26 March 2019

Advent Access to join Stanford StartX community

12 March 2019 | News

Advent Access and its Founder are the first medical device startup in Singapore to be selected to join the community of the best Stanford and Silicon Valley entrepreneurs

image credit- sgsme.sg

image credit- sgsme.sg

Advent Access (Advent), one of Singapore’s most innovative medtech companies, has announced that it has been selected by StartX to be part of its 2019 Spring cohort. StartX is an educational non-profit organization with the mission to accelerate the development of top entrepreneurs in the Stanford University network. Advent Access and its founder are accepted into the program in recognition of their strong potential to achieve a medical breakthrough in the development of its award-winning av-Guardian technology for hemodialysis.

StartX is a community of serial entrepreneurs, industry experts, tenured Stanford professors, and well-funded growth-stage startups. To date, over 650 StartX companies have raised US$6.7 billion in funding. Among the medical companies in the community, US$1.8 billion has been raised by approximately 160 companies and 24 Food and Drug Administration approvals have been obtained. Companies undergo a rigorous selection process and the program is highly competitive. Historically only eight per cent of applicants are accepted from a pool of around 300 applicant companies per batch.

Advent Access will leverage the powerful networks, resources and funding available through StartX as it continues the late-stage development of its av-Guardian technology. The av-Guardian is the world’s first medical implant to pioneer the concept of having a “guardian guide-door” for dialysis needles to optimally enter a specially created dialysis vein, an arteriovenous fistula (AV fistula), without the implant being in contact with the vein. Advent Access is currently conducting a second clinical study to evaluate the potential for av-Guardian to assist in self-cannulation and, ultimately, to enable more patients to benefit from home or self-hemodialysis. Advent expects to complete the study later in 2019.

Peh Ruey Feng, Founder and Chief Executive Officer of Advent Access, said: “This is an exciting time for Advent Access as we approach important milestones for the company in 2019. Our selection to join the StartX program is further validation of the work of our team in pioneering a potential solution to one of the biggest needs in hemodialysis today – easy and reliable access to the AV fistula that ultimately improves patient outcomes, comfort, and unlock novel care environments. We look forward to collaborating closely with the StartX community members and the access to Stanford’s wide network of corporate partners and investors.”

Joseph Huang, Chief Executive Officer of StartX, added: ”We are delighted to welcome Ruey Feng Peh and Advent Access to the StartX community. We believe that entrepreneurs can achieve far more as a group than they can as individuals and we have seen strong evidence of this in the high number of companies within StartX reaching a valuation of more than US$100m. Advent Access joins our group at a time when global healthcare payors are calling for a transformation in the treatment of kidney disease by moving care into the home setting to lower costs. We are excited to work with Ruey to realise his vision of the av-Guardian in addressing that exact need.”

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Podcast

 

Survey Box

Are policy innovations key to address the healthcare challenges in Asia?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls